Albiglutide

Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on April 15, 2014 by the FDA.

用于2型糖尿病成年患者，作为饮食和运动的辅助疗法以改善血糖控制。不推荐用于饮食和运动控制不佳患者的一线治疗。